Pain Therapeutics reiterated at hold by Citigroup

Pain Therapeutics was reiterated at a hold rating and a target price of $8 by Citigroup analyst Andrew Swanson. The company reported a fourth-quarter loss of $0.07 per share versus a $0.22 loss in the year-ago period. Citigroup raised its earnings-per-share forecast for 2006 to a loss of $0.07 from a $0.16 loss, and 2007 to a profit of $0.04 from a $0.13 loss. Shares of the South San Francisco, Calif., drug development company were up 19 cents, or 2.50%, at $7.79 on volume of 602,464 shares versus the three-month running average of 543,410 shares. (Nasdaq: PTIE).

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.